[go: up one dir, main page]

DK1144006T3 - Synergistisk inhibering af HIV-1-fusion og -binding, præparater og antistoffer dertil - Google Patents

Synergistisk inhibering af HIV-1-fusion og -binding, præparater og antistoffer dertil

Info

Publication number
DK1144006T3
DK1144006T3 DK99966466T DK99966466T DK1144006T3 DK 1144006 T3 DK1144006 T3 DK 1144006T3 DK 99966466 T DK99966466 T DK 99966466T DK 99966466 T DK99966466 T DK 99966466T DK 1144006 T3 DK1144006 T3 DK 1144006T3
Authority
DK
Denmark
Prior art keywords
hiv
antibodies
preparations
fusion
binding
Prior art date
Application number
DK99966466T
Other languages
English (en)
Inventor
William C Olson
Paul J Maddon
Original Assignee
Progenics Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc filed Critical Progenics Pharm Inc
Application granted granted Critical
Publication of DK1144006T3 publication Critical patent/DK1144006T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK99966466T 1998-12-16 1999-12-16 Synergistisk inhibering af HIV-1-fusion og -binding, præparater og antistoffer dertil DK1144006T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21279398A 1998-12-16 1998-12-16
US11253298P 1998-12-16 1998-12-16
PCT/US1999/030345 WO2000035409A2 (en) 1998-12-16 1999-12-16 Hiv-i fusion inhibition compounds

Publications (1)

Publication Number Publication Date
DK1144006T3 true DK1144006T3 (da) 2007-11-26

Family

ID=26810060

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99966466T DK1144006T3 (da) 1998-12-16 1999-12-16 Synergistisk inhibering af HIV-1-fusion og -binding, præparater og antistoffer dertil

Country Status (13)

Country Link
EP (2) EP2088158A3 (da)
JP (1) JP2002538771A (da)
AT (1) ATE375802T1 (da)
AU (3) AU773175B2 (da)
CA (1) CA2355607A1 (da)
CY (1) CY1107858T1 (da)
DE (1) DE69937369T2 (da)
DK (1) DK1144006T3 (da)
ES (1) ES2296416T3 (da)
HK (1) HK1041207B (da)
MX (1) MXPA01006097A (da)
PT (1) PT1144006E (da)
WO (1) WO2000035409A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0847452B1 (en) 1995-06-07 2009-04-01 Progenics Pharmaceuticals, Inc. Monoclonal antibody for inhibiting hiv-1 envelope glycoprotein mediated membrane fusion
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US20020146415A1 (en) * 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US20060078537A1 (en) * 2001-12-21 2006-04-13 Matthias Mack Mono-and dual chemokine/cytokine constructs
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
DK1478738T3 (da) * 2002-02-22 2009-03-09 Pdl Biopharma Inc Anti-CCR5-antistof
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
CN101410414A (zh) * 2006-01-30 2009-04-15 弗·哈夫曼-拉罗切有限公司 用于治疗hiv的具有协同作用的组合物
CA2658474A1 (en) 2006-08-17 2008-02-21 F.Hoffmann-La Roche Ag A conjugate of an antibody against ccr5 and an antifusogenic peptide
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
MX2009002694A (es) 2006-09-29 2009-03-24 Hoffmann La Roche Anticuerpos dirigidos contra ccr5 y usos de los mismos.
US20090143288A1 (en) 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045543A2 (en) * 1996-05-28 1997-12-04 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Cc chemokine receptor 5, antibodies thereto, transgenic animals
WO1997047319A1 (en) * 1996-06-14 1997-12-18 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting hiv-1 infection
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same

Also Published As

Publication number Publication date
EP1144006A4 (en) 2004-11-24
EP1144006A2 (en) 2001-10-17
WO2000035409A3 (en) 2000-09-14
EP2088158A2 (en) 2009-08-12
AU773175B2 (en) 2004-05-20
CA2355607A1 (en) 2000-06-22
EP2088158A3 (en) 2010-01-20
CY1107858T1 (el) 2013-06-19
EP1144006B1 (en) 2007-10-17
WO2000035409A2 (en) 2000-06-22
AU2004205165A1 (en) 2004-09-16
AU2199600A (en) 2000-07-03
HK1041207A1 (en) 2002-07-05
MXPA01006097A (es) 2002-04-15
JP2002538771A (ja) 2002-11-19
DE69937369T2 (de) 2008-07-24
AU2004205164A1 (en) 2004-09-16
ES2296416T3 (es) 2008-04-16
DE69937369D1 (de) 2007-11-29
ATE375802T1 (de) 2007-11-15
PT1144006E (pt) 2007-12-11
HK1041207B (en) 2007-12-28

Similar Documents

Publication Publication Date Title
CY1107858T1 (el) Ccr5 αντισωματα pa14
DE69429095D1 (de) Humanisierte antikoerper
KR960704938A (ko) Fas 길항제 및 그의 용도(Fas Antagonists and Uses Thereof)
NO942912L (no) Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
ATE324381T1 (de) Mutiertes scfv-fragment des okt-3 antikörpers
KR960704576A (ko) CD40에 대한 항체(Antibodies to CD40)
PE20001316A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene
ES2187954T3 (es) Anticuerpos anti-integrina avb3 antagonistas.
WO2003078468A3 (de) Verwendung einer an cd28 bindenden wirksubstanz zur herstellung einer pharmazeutischen zusammensetzung
EP2186884A3 (en) HCV-anti-core monoclonal antibody
DK1860188T3 (da) Human cytokin-receptor
CA2221893A1 (fr) Anticorps specifique de staphylococcus aureus et utilisations
WO2003048194A3 (de) Peptid oder protein enthaltend ein c'-d loop der cd28 rezeptorfamilie
AU2707992A (en) Monoclonal antibodies to hepatitis c virus
MX9702422A (es) Anticuerpos recombinantes contra fas y adn para los mismos.
EP0155172A3 (en) Anti-human lung cancer monoclonal antibodies
BR9702101A (pt) Hibridoma e anticorpo monoclonal
BR0007827A (pt) Anticorpos e fragmento fv que reconhecemantìgeno ior c2
CA2137551A1 (en) A novel endothelial cell molecule mediating lymphocyte binding in man
DK1161522T3 (da) Fremgangsmåde til isolering af CD8+-celler og beslægtede hybridomaceller, antistoffer og polypeptider
EP0349258A3 (en) Method of determining the differentiation of a human t-cell
DK557187D0 (da) Murin hybridoma lym-1, dermed fremstillet monoklonalt antistof og fremgangsmaade til fremstilling af antistoffet
DK557287D0 (da) Murin hybridoma lym-2, dermed fremstillet monoklonalt antistof og fremangsmaade til fremstilling af antistoffet